For research and educational purposes only. Not intended for human consumption.
Ara 290
Well Researched- •FDA Orphan Drug status
- •23% nerve fiber increase in trials
- •Multiple Phase 2 trials completed
Tissue-Protective Peptide | Innate Repair Receptor Agonist | Cibinetide
Overview
What is Ara 290?
Ara 290 (Cibinetide) is an engineered 11-amino acid peptide derived from erythropoietin that activates the Innate Repair Receptor (IRR) to provide tissue-protective effects without stimulating red blood cell production. It has completed multiple Phase 2 clinical trials and holds FDA Orphan Drug status for several indications.
Key Benefits
Proven tissue protection, nerve regeneration (23% increase in corneal nerve fibers), anti-inflammatory effects, excellent safety profile in clinical trials, no erythropoietic effects.
Mechanism of Action
Activates Innate Repair Receptor (IRR) through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects.
Molecular Information
Pharmacokinetics
Research Indications
Peripheral Nerve Regeneration
23% increase in corneal nerve fiber area in clinical trials.
Diabetic Neuropathy
Significant nerve regeneration in Type 2 diabetes patients.
CNS Protection
Crosses blood-brain barrier for neuroprotection in stroke models.
Research Protocols
Disclaimer: Ara 290 has completed Phase 2 trials. FDA Orphan Drug status for sarcoidosis-associated neuropathy.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Neuropathy Treatment | 4 mg | Once daily | Subcutaneous |
| Tissue Protection | 1-8 mg | Once daily | Subcutaneous |
| Research Protocol | 4 mg | Once daily x 28 days | Subcutaneous |
Timing: Morning administration may optimize circadian alignment with tissue repair. Short half-life but triggers long-lasting cellular effects.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow vial to reach room temp
Clean vial top with alcohol
Slowly inject 1 mL sterile water
Gently swirl to dissolve
Solution may be slightly cloudy - normal
Use immediately or refrigerate up to 24 hours
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Pharmaceutical grade GMP
Clinical trial material with full documentation.
Correct peptide sequence
11-amino acid with N-terminal pyroglutamate.
Light-sensitive
Protect from light during storage and use.
Discolored solution
Should be clear to slightly cloudy and colorless.
What to Expect
- •Week 1-2: Initial anti-inflammatory effects, mild pain improvement
- •Week 2-4: Progressive nerve regeneration, enhanced healing
- •Week 4-6: Peak therapeutic effects, maximum nerve fiber improvements
- •Month 2-6: Long-lasting benefits due to 'molecular switch' effect
Side Effects & Safety
Side Effects
- •Excellent safety in clinical trials - no serious drug-related events
- •No anti-drug antibodies detected
- •No erythropoietic effects (no polycythemia risk)
- •Contraindicated with recent anti-TNF therapy (6 months) or EPO (2 months)
- •Not recommended BMI >34 or during pregnancy
When to Stop
- •Injection site reactions
- •Any serious adverse effects
- •As directed by healthcare provider
References
2 StudiesSarcoidosis Neuropathy Phase 2b (2017)
Human | 64 patients | 28 days | 23% nerve fiber increase at 4mg
Double-blind, placebo-controlled showing significant nerve regeneration and pain reduction.
Diabetic Macular Edema Pilot (2020)
Human | 9 patients | 12 weeks | Improved quality of life
Open-label pilot showing good safety and improved patient outcomes.
Quick Start Guide
Research Disclaimer
Ara 290 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Ara 290 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Ara 290 for any purpose. Consult qualified professionals for any research applications.